杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2018/09/28 | 2,440 | 2,440 | 2,339 | 2,346 | -73 | -3% | 394,500 |
2018/09/27 | 2,512 | 2,534 | 2,385 | 2,419 | -45 | -1.8% | 505,300 |
2018/09/26 | 2,479 | 2,479 | 2,407 | 2,464 | -38 | -1.5% | 172,500 |
2018/09/25 | 2,394 | 2,506 | 2,368 | 2,502 | +161 | +6.9% | 365,200 |
2018/09/21 | 2,352 | 2,372 | 2,338 | 2,341 | +9 | +0.4% | 228,300 |
2018/09/20 | 2,357 | 2,357 | 2,324 | 2,332 | -23 | -1% | 125,800 |
2018/09/19 | 2,320 | 2,371 | 2,314 | 2,355 | +58 | +2.5% | 255,800 |
2018/09/18 | 2,231 | 2,301 | 2,198 | 2,297 | +47 | +2.1% | 168,600 |
2018/09/14 | 2,261 | 2,274 | 2,222 | 2,250 | -3 | -0.1% | 126,300 |
2018/09/13 | 2,242 | 2,278 | 2,237 | 2,253 | +8 | +0.4% | 85,500 |
2018/09/12 | 2,217 | 2,252 | 2,200 | 2,245 | +24 | +1.1% | 242,900 |
2018/09/11 | 2,187 | 2,230 | 2,180 | 2,221 | +49 | +2.3% | 162,800 |
2018/09/10 | 2,185 | 2,200 | 2,169 | 2,172 | -2 | -0.1% | 105,900 |
2018/09/07 | 2,150 | 2,177 | 2,136 | 2,174 | +3 | +0.1% | 96,100 |
2018/09/06 | 2,179 | 2,186 | 2,157 | 2,171 | -8 | -0.4% | 156,700 |
2018/09/05 | 2,235 | 2,235 | 2,170 | 2,179 | -55 | -2.5% | 220,300 |
2018/09/04 | 2,267 | 2,267 | 2,233 | 2,234 | -26 | -1.2% | 105,700 |
2018/09/03 | 2,308 | 2,310 | 2,249 | 2,260 | -48 | -2.1% | 159,600 |
2018/08/31 | 2,271 | 2,319 | 2,259 | 2,308 | +11 | +0.5% | 114,000 |
2018/08/30 | 2,247 | 2,302 | 2,233 | 2,297 | +65 | +2.9% | 209,500 |
2018/08/29 | 2,206 | 2,236 | 2,196 | 2,232 | +25 | +1.1% | 109,200 |
2018/08/28 | 2,232 | 2,232 | 2,202 | 2,207 | -17 | -0.8% | 116,100 |
2018/08/27 | 2,205 | 2,225 | 2,197 | 2,224 | +18 | +0.8% | 110,600 |
2018/08/24 | 2,220 | 2,230 | 2,201 | 2,206 | -4 | -0.2% | 93,200 |
2018/08/23 | 2,183 | 2,214 | 2,182 | 2,210 | +33 | +1.5% | 75,100 |
2018/08/22 | 2,162 | 2,191 | 2,156 | 2,177 | +19 | +0.9% | 68,900 |
2018/08/21 | 2,159 | 2,163 | 2,138 | 2,158 | ±0 | ±0% | 50,300 |
2018/08/20 | 2,180 | 2,193 | 2,154 | 2,158 | -45 | -2% | 52,600 |
2018/08/17 | 2,169 | 2,206 | 2,169 | 2,203 | +23 | +1.1% | 57,400 |
2018/08/16 | 2,219 | 2,231 | 2,174 | 2,180 | -61 | -2.7% | 109,600 |
2018/08/15 | 2,215 | 2,252 | 2,215 | 2,241 | +35 | +1.6% | 121,000 |
2018/08/14 | 2,195 | 2,214 | 2,188 | 2,206 | ±0 | ±0% | 75,300 |
2018/08/13 | 2,222 | 2,250 | 2,206 | 2,206 | -36 | -1.6% | 104,300 |
2018/08/10 | 2,254 | 2,268 | 2,235 | 2,242 | +2 | +0.1% | 139,200 |
2018/08/09 | 2,260 | 2,269 | 2,235 | 2,240 | -9 | -0.4% | 138,400 |
2018/08/08 | 2,242 | 2,259 | 2,238 | 2,249 | +8 | +0.4% | 113,700 |
2018/08/07 | 2,235 | 2,243 | 2,212 | 2,241 | +5 | +0.2% | 70,900 |
2018/08/06 | 2,230 | 2,254 | 2,225 | 2,236 | +18 | +0.8% | 69,900 |
2018/08/03 | 2,223 | 2,236 | 2,191 | 2,218 | -3 | -0.1% | 145,100 |
2018/08/02 | 2,274 | 2,280 | 2,213 | 2,221 | -51 | -2.2% | 136,100 |
2018/08/01 | 2,298 | 2,307 | 2,257 | 2,272 | +3 | +0.1% | 181,900 |
2018/07/31 | 2,262 | 2,330 | 2,242 | 2,269 | +9 | +0.4% | 272,500 |
2018/07/30 | 2,285 | 2,291 | 2,260 | 2,260 | -42 | -1.8% | 57,300 |
2018/07/27 | 2,319 | 2,319 | 2,290 | 2,302 | -13 | -0.6% | 78,500 |
2018/07/26 | 2,280 | 2,320 | 2,259 | 2,315 | +56 | +2.5% | 94,800 |
2018/07/25 | 2,277 | 2,277 | 2,249 | 2,259 | +1 | ±0% | 66,300 |
2018/07/24 | 2,280 | 2,283 | 2,254 | 2,258 | -8 | -0.4% | 52,700 |
2018/07/23 | 2,249 | 2,275 | 2,233 | 2,266 | +17 | +0.8% | 83,400 |
2018/07/20 | 2,257 | 2,267 | 2,237 | 2,249 | -23 | -1% | 78,100 |
2018/07/19 | 2,268 | 2,278 | 2,255 | 2,272 | +4 | +0.2% | 105,700 |
1501~
1550
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム